A
AN2 Therapeutics D
D
ANTX
1.39500
USD
-0.01
(-0.36%)
Market Closed
Volume
17,561
EPS
-2
Div Yield
-
P/E
-1
Market Cap
41,681,052
Novo Nordisk Surges in Profit and Sales
6 months ago
Stocks news More
Title: AN2 Therapeutics
Sector: Healthcare
Industry: Biotechnology
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.